Mr. Patrick has served as Chief Executive Officer and as a member of the board of directors of Armata Pharmaceuticals since May 2019, following the merger of C3J Therapeutics and AmpliPhi Biosciences. Mr. Patrick served as President and Chief Executive Officer of C3J Therapeutics since 2010, and as a member of the board of directors since 2009. Previously, Todd served as President and Chief Operating Officer of ID Biomedical Corporation. Mr. Patrick joined ID Biomedical in 1994 when he became the first employee of the Company’s vaccine subsidiary. Todd remained with ID Biomedical as its President until 2005, when GlaxoSmithKline purchased the Company for $1.5 billion. Upon retiring from ID Biomedical, Mr. Patrick and a group of investors raised over $100 million to invest in several biomedical companies where Todd served as a director and consultant. Before he joined ID Biomedical, Mr. Patrick was appointed as the first Director of the Office of Intellectual Property Administration at UCLA, helping the organization start its IP program in 1989. Mr. Patrick is the past Chairman of the Board of Trustees for the Seattle Biomedical Research Institute, a 400-person, non-profit global health organization focused on creating new drugs and vaccines to treat infectious diseases in the developing world. Todd currently serves on the board of directors of CRH Medical Corporation (NYSE American: CRHM); Sunniva, Inc.; and InvVax, Inc. He is also on the board of the non-profit Foster Foundation.
Dr. Varnum is a biotech veteran with more than 25 years of experience. Dr. Varnum joined C3J Therapeutics in 2012 as Vice President of Product Development, stepping into the role of Chief Development Officer in 2014, a role he continues to serve at Armata Pharmaceuticals. Dr. Varnum began his career with Amgen and spent more than 18 years at the biotech pioneer as that company grew from a start-up to a large and successful biotechnology company. He started in discovery research where his team purified novel growth factors and advanced antibodies and small molecules into clinical studies. Dr. Varnum also worked in development, assisting with clinical development of proteins, antibodies and small molecules. In this capacity, he contributed to key regulatory filings, market research and product launch, giving him experience in drug discovery and development from the lab bench to product launch and marketing. After retiring from Amgen in 2007, Dr. Varnum turned his focus to the start-up landscape, working in several capacities, including assisting investors, entrepreneurs and start-ups in the assessment of technologies for funding or in-licensing. In these capacities, he established research strategies and plans, and served as CSO for several companies, securing funding, and executing research contracts with large and mid-sized pharmaceutical companies. Dr. Varnum obtained his Ph.D. from UCLA studying oncogenes, and his drug development research experience includes hematopoietic growth factor discovery, oncology, auto-immune/inflammatory disorders, personalized medicine in IBD and infectious diseases.
Mr. Martin served as Chief Financial Officer of AmpliPhi Biosciences since January 2016, a role he continues to serve at Armata Pharmaceuticals. Previously, Mr. Martin served as Senior Vice President and Chief Financial Officer of Applied Proteomics, Inc., a molecular diagnostics company, from December 2014 to August 2015. From June 2011 to December 2014, Mr. Martin served as Senior Vice President and Chief Financial Officer of Apricus Biosciences, Inc., a publicly traded pharmaceutical company, and served as the Interim Chief Executive Officer of Apricus from November 2012 through March 2013. From 2008 to January 2011, Mr. Martin served as Senior Vice President and Chief Financial Officer of BakBone Software, a publicly traded software company. During his final 10 months with BakBone until the company’s acquisition in January 2011, Mr. Martin also served as BakBone’s Interim Chief Executive Officer. From 2005 to 2007, Mr. Martin served as Chief Financial Officer of Stratagene Corporation, a publicly traded research products and clinical diagnostics company. Mr. Martin’s previous experience also includes serving as Controller with Gen-Probe Incorporated, a publicly traded molecular diagnostics company, as well as 10 years with Deloitte & Touche LLP, a public accounting firm. Mr. Martin holds a B.S. degree from San Diego State University and is a certified public accountant (inactive).
Mr. Morris leads the production, quality, facilities, and clinical operations areas for Armata Pharmaceuticals, a role he also held at C3J Therapeutics since joining the company in 2012. Previously, Mr. Morris was the Chief Operating Officer at Response Biomedical in Vancouver, Canada. While at Response Biomedical, Mr. Morris directed the expansion of manufacturing facilities and scale-up of in-vitro diagnostic products. Prior to his tenure at Response, Mr. Morris was responsible for all manufacturing and quality control activities for ID Biomedical Corporation until its acquisition by GlaxoSmithKline (GSK). Mr. Morris was then responsible for all North American Operations which included influenza vaccine production for GSK. Mr. Morris started his career at Syntex Corporation in Palo Alto, where he spent 21 years in increasingly responsible positions, ultimately becoming the Director of Pharmaceutical Manufacturing. Mr. Morris earned his BA in Management from Saint Mary’s College in Moraga, California.
An established scientist with 20 years of experience working with bacteriophage, Dr. Barbu leads the discovery and engineering efforts for Armata’s pipeline of natural and synthetic phage therapeutics programs. Dr. Barbu combines her deep expertise in molecular biology, phage biology, bacterial pathogenesis and antimicrobial drug development, to set strategy and deliver key preclinical data essential for advancing Armata’s phage programs from bench to clinic. Previously, she spent 5 years at Synthetic Genomics, Inc., spearheading the development of the phage engineering program, securing non-dilutive funding and a partnership with a global pharmaceutical company that further supported the development of the synthetic phage platform. This phage engineering platform and related assets were acquired by C3J Therapeutics (now Armata Pharmaceuticals) in February 2018 and Dr. Barbu became the Senior Director of Synthetic Biology at the Company. Dr. Barbu’s career in industry began at an oil and gas company, where for more than 5 years she co-led the development of new methods for bioremediation and biocontrol. Dr. Barbu earned her Ph.D. in Microbiology/Molecular Genetics and Biochemistry from the University of Texas Health Science Center at Houston. She completed her postdoctoral training at the MD Anderson Cancer Center, identifying druggable targets for cancer and infectious diseases using in vivo and in vitro phage display. Dr. Barbu has authored numerous peer-reviewed publications, presented worldwide as an invited speaker and received private and government grants for her research in antimicrobial therapeutics and synthetic biology. She has several issued and pending patents.
Dr. Jones is a pulmonary-critical care medicine specialist and physician-researcher with more than 20 years’ experience practicing medicine and conducting basic, translational and clinical research.
Dr. Jones leads Armata’s clinical development efforts with the goal of advancing its natural and synthetic phage product candidates through randomized controlled trials, supporting a path to registration. Dr. Jones continues to spend a small percentage of her time practicing critical care medicine, which allows her to remain connected to patients with life-threatening infections whom Armata is committed to helping with phage therapy.
Previously, Dr. Jones served as Director of the Lung Imaging Program, Biomedical Imaging Research Institute, and Attending physician in the medical intensive care unit at Cedars-Sinai Medical Center in Los Angeles. Her academic appointments included Associate Professor of Medicine and Biomedical Sciences at Cedars-Sinai, as well as Health Sciences Associate Clinical Professor at the David Geffen School of Medicine at the University of California, Los Angeles. Dr. Jones’s prior research focused on acute lung injury and novel lung imaging techniques. Dr. Jones has authored numerous peer-reviewed publications, delivered numerous invited presentations and received private and government grants including KL2 and K08 grants from the National Institutes of Health.
Dr. Jones earned her BA in Molecular and Cell Biology with Honors from the University of California, Berkley and a Doctor of Medicine, Magna Cum Laude, from the Medical College of Pennsylvania/Hahnemann University (now Drexel Medical School). Dr. Jones completed her residency in Internal Medicine at Boston Medical Center and her pulmonary and critical care fellowship training at Johns Hopkins Hospital, followed by an extended research fellowship at the Pulmonary Branch of the National Heart, Lung and Blood Institute.